Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe

•Interim data from a prospective observational study of adjunctive brivaracetam in Europe.•In patients with drug-resistant focal seizures, the 6-month retention rate was 62.1 %.•At 6 months of treatment, 53.6 % of patients were 50 % responders, and 7.5 % were seizure-free.•44.2 % of patients had improved and 15.4 % had worsened health-related quality of life from Baseline.•In this real-world study, brivaracetam was well tolerated and no new safety signals were observed.